Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

Health for all: Innovative strategies for global medicine accessibility

Strategic partnerships between governments, the private sector, and NGOs are essential to making global medicine access a reality.

Health for all: Innovative strategies for global medicine accessibility

[Syda Productions / Adobe Stock]

Profile photo of Scott Lyman

CEO · Belhaven Biopharma

Access to essential, life-saving medicines remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Despite advancements in global health, these improvements often fail to reach those who need them most. Many are left unable to afford or obtain necessary treatments, resulting in gaps in care for a number of treatable diseases.

This disparity is exacerbated by healthcare companies and investors prioritizing more lucrative markets, leaving LMICs behind in the queue for vaccines and critical medicines. The consequences of this inequity not only devastate local populations, but also threaten global health security, as the COVID-19 pandemic has clearly demonstrated.

Addressing this crisis requires a unified effort from healthcare organizations to prioritize equitable access to essential medicines. While daunting, several strategies can help combat this global issue.

BARRIERS TO EQUITABLE MEDICINE ACCESS

Barriers to equitable medicine distribution are multifaceted. A primary challenge is the logistical difficulty of delivering medications to underserved areas. Many essential drugs require specialized storage, such as refrigeration or careful handling, which is hard to maintain in regions with limited infrastructure. Additionally, supply chains for distributing medicines are often fragile, particularly in remote areas where healthcare facilities may be sparse or poorly equipped. As a result, essential treatments can be delayed or unavailable, especially in LMICs.

Regulatory delays, including complex approval processes, prevent new treatments from reaching patients in a timely manner. These barriers trap underserved populations in a cycle of limited access to life-saving medicines.

Cultural and educational barriers also hinder access. A lack of awareness or misconceptions about medical conditions and treatments can discourage people from seeking care or adhering to prescribed therapies. The absence of adequate educational campaigns leaves people unaware of available healthcare options. These gaps deepen the fight for equitable access to medicines.

Economic factors further shape access to life-saving medicines. Additionally, focusing on minimizing production costs ensures profitability for partners while keeping the medication accessible. By addressing stability and cost-efficiency, we can help bridge gaps in healthcare access without compromising quality or affordability. A key advantage of our own Nasdepi © is its longer shelf life and resilience to temperature fluctuations, reducing waste and logistical challenges. These benefits strengthen the pharmaco-economic case for adoption, allowing pharmaceutical partners to offer it at a sustainable price. 

REIMAGINING GLOBAL MEDICINE DISTRIBUTION

To address these barriers, we must rethink how medicines are made and distributed. Innovations in shelf-stable drug formulations, packaging that doesn’t require refrigeration, and decentralized manufacturing could transform healthcare delivery, particularly in remote areas. Beyond the medicines themselves, direct-to-patient delivery, mobile clinics, and digital health tools are already helping to bridge the gap and offer more flexible alternatives to traditional healthcare systems.

Strategic partnerships are also essential to improving access to medicine. Collaboration among governments, international organizations, NGOs, and the private sector can lead to more efficient and sustainable healthcare delivery. Initiatives like GAVI, the Vaccine Alliance, have shown the power of such partnerships in improving vaccine availability in LMICs, helping to build lasting healthcare infrastructure. Pooling purchasing power among countries enables them to negotiate better prices with pharmaceutical companies, reducing the cost of life-saving medicines.

Technology plays an increasingly important role in improving medicine distribution. Mobile health apps and telemedicine platforms can bridge the gap between remote populations and healthcare services. These innovations facilitate consultations, patient monitoring, and medicine distribution, overcoming geographical and infrastructural barriers. When combined with better training for healthcare workers and enhanced community engagement, these solutions offer the potential for a more equitable global healthcare system.

EPINEPHRINE AS A CASE STUDY IN ACCESSIBILITY

The challenges surrounding global access to critical medications are evident in emergency treatments such as epinephrine for anaphylaxis. Despite being the gold standard for managing severe allergic reactions, epinephrine auto-injectors are available in only 60% of countries, with the majority in high-income regions. Many countries in South America, Africa, and Asia-Pacific either lack access to these life-saving devices or rely on costly, inconsistent importation, further compounding the problem.

One obstacle to widespread epinephrine access is the reliance on auto-injectors, which require strict temperature control, have a limited shelf life, and are expensive to produce. In regions with hot climates and unreliable refrigeration, these factors present significant challenges. However, innovations in drug delivery, such as dry powder nasal formulations, offer a promising alternative. These needle-free, heat-stable nasal formulations, such as our own Nasdepi, do not require refrigeration and provide protection from extreme heat and humidity. By reducing logistical burdens and extending expiration dating, these advancements could make emergency allergy treatments more accessible worldwide, regardless of geographic or resource constraints.

A PATH FORWARD

Solving the challenge of global medicine access requires a multi-pronged approach that combines innovation with strategic collaboration. While infrastructure improvements are essential, the key to overcoming the limitations of traditional healthcare systems lies in adopting scalable, sustainable innovations, such as shelf-stable drug formulations, decreased manufacturing costs, and mobile health technologies. These innovations can reduce the logistical and economic barriers that prevent life-saving treatments from reaching those in need.

Strategic partnerships between governments, the private sector, and NGOs are essential to making global medicine access a reality. By pooling resources and fostering collaboration, countries, particularly those in LMICs, can bypass supply chain and price barriers, negotiate better terms, and build lasting healthcare infrastructure. The role of technology cannot be overstated—mobile health apps, telemedicine, and new drug delivery methods can bridge the gap between remote populations and critical treatments. The future of global medicine distribution depends on these adaptive solutions, which have the potential to transform healthcare systems and make essential medicines universally accessible, ultimately making health for all a fundamental human right.